EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Source: SeekingAlpha
2025-06-12 11:03:51 ET
Investment Overview
Back in January this year, I covered EyePoint Pharmaceuticals, Inc. ( EYPT ) in a note for Seeking Alpha , calling its stock a "risky buy" ahead of a key readout for its lead and only clinical stage drug candidate Duravyu - vorolanib intravitreal insert - in patients suffering from diabetic macular edema - a serious eye condition that can result in vision loss....
Read the full article on Seeking Alpha
For further details see:
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Clearside Biomedical Inc.
NASDAQ: CLSD
CLSD Trading
-90.6% G/L:
$0.41 Last:
1,945,057 Volume:
$0.57 Open:
CLSD Latest News
November 24, 2025 07:05:00 am
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
CLSD Stock Data
$3,521,323
4,883,304
0.23%
26
757199%
Biotechnology & Life Sciences
Healthcare
US
Alpharetta
